There is evidence that @entity440 treatment of @entity5345 and @entity2674 carriers for prior @entity0 increases risk of @entity1204 (EC), and suggestive evidence that @entity5345 and @entity2674 mutation carriers may be predisposed to EC in the absence of @entity440 exposure. We assessed the association of EC with @entity5345 or @entity2674 mutation status in Australasian @entity5344 . Report of at least one case of EC was significantly greater in @entity5345 -positive families (35/218 (16%); p = .03) and non-significantly greater in @entity2674 -positive families (23/189 (12%); p = .6), compared to high-risk @entity0 families without a @entity6069 mutation (86/796 (11%)). EC was the first/concurrent @entity5 for 41% of EC cases with @entity5 diagnoses from @entity6069 families, and early onset for most of these diagnoses. Mutation status was imputed for ungeno-typed individuals from 57 @entity6069 pedigrees reporting EC using BRCAPRO. Effects of genotype on EC diagnosis age, and interaction with @entity440 therapy, were assessed using Cox proportional hazards regression analysis. EC risk was non-significantly marginally greater for @entity5345 carriers (hazard ratio = 1.25, 95%CI = 0.65-2.41), and @entity2674 carriers (HR = 1.12, 95%CI = 0.51-2.45), compared to non-carrier family members. @entity440 therapy was highly significantly associated with EC (HR = 6.68, 95%CI = 3.12-15.15; p = 1.7 x 10(-6)) in @entity6069 families, with no evidence for interaction between @entity440 therapy and @entity6069 genotype. Our family-based study supports a 7-fold increase in EC risk with @entity440 exposure for female family members from @entity6069 families. Early onset EC in carriers without @entity440 use suggests that further study is required to assess association of modest EC risk with @entity5345 /2 mutation status alone.

Report of @entity1204 in Australian XXXX and @entity2674 mutation-positive Families.

@entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrioid subtype endometrial cancer'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen', 'Tamoxifen'] @entity5344 :: ('MESH:D061325', 'Disease') :: ['breast-ovarian families'] @entity5345 :: ('672', 'Gene') :: ['BRCA1'] @entity5 :: ('MESH:D009369', 'Disease') :: ['multiple cancer', 'cancer'] @entity2674 :: ('675', 'Gene') :: ['BRCA2'] @entity6069 :: ('672;675', 'Gene') :: ['BRCA1/2']
@entity5345 :: (672,Gene) :: ['BRCA1']
